

Press release, March 22, 2017

Alligator Bioscience Annual Report for 2016 published

Lund, Sweden - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announces that that the Swedish version of Annual Report for 2016 now is available at the company's website, the English version will be posted next week. www.alligatorbioscience.com

For further information, please contact:

Per Norlén, CEO

Telephone: + 46 46 286 42 80 (switchboard)

E-mail: per.norlen@alligatorbioscience.com

Rein Piir, VP Investor Relations

Telephone: +46 708 537292

E-mail: rein.piir@alligatorbioscience.com

Per-Olof Schrewelius, CFO

Telephone: +46 46 286 42 85

E-mail: per-olof.schrewelius@alligatorbioscience.com

The information in the press release is such that Alligator Bioscience AB is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 16.00 CET on 22 March, 2017.

About Alligator Bioscience

Alligator is a biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company has a pipeline of lead clinical and preclinical product candidates: ADC-1013, ATOR-1015 and ATOR-1016 as well as various research candidates. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The Company's shares are listed on Nasdaq Stockholm under the ticker "ATORX". The Company is headquartered in Lund, Sweden, and has approximately 40 employees. For more information, please visit www.alligatorbioscience.com.